1. A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults. (1st February 2017) Authors: Huhn, Gregory D.; Tebas, Pablo; Gallant, Joel; Wilkin, Timothy; Cheng, Andrew; Yan, Mingjin; Zhong, Lijie; Callebaut, Christian; Custodio, Joseph M.; Fordyce, Marshall W.; Das, Moupali; McCallister, Scott Journal: Journal of acquired immune deficiency syndromes Issue: Volume 74:Number 2(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate. (11th November 2019) Authors: Huhn, Gregory D; Shamblaw, David J; Baril, Jean-Guy; Hsue, Priscilla Y; Mills, Brittany L; Nguyen-Cleary, Thai; McCallister, Scott; Das, Moupali Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults. (1st November 2016) Authors: Gallant, Joel; Brunetta, Jason; Crofoot, Gordon; Benson, Paul; Mills, Anthony; Brinson, Cynthia; Oka, Shinichi; Cheng, Andrew; Garner, Will; Fordyce, Marshall; Das, Moupali; McCallister, Scott Journal: Journal of acquired immune deficiency syndromes Issue: Volume 73:Number 3(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment. (1st June 2017) Authors: Arribas, José R.; Thompson, Melanie; Sax, Paul E.; Haas, Bernhard; McDonald, Cheryl; Wohl, David A.; DeJesus, Edwin; Clarke, Amanda E.; Guo, Susan; Wang, Hui; Callebaut, Christian; Plummer, Andrew; Cheng, Andrew; Das, Moupali; McCallister, Scott Journal: Journal of acquired immune deficiency syndromes Issue: Volume 75:Number 2(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Demographic diversity of US-based participants in GSK-sponsored interventional clinical trials. (April 2023) Authors: Reid, Michel M; Davis, Scott P; Henry, Ouzama N; Mathew, Ashwin A; McCallister, Scott; Nero, Taj T; Rabheru, Sanjit A; Sampson, Shani H; Vanderslice, Tracy F; Williams, Danaé T Journal: Clinical trials Issue: Volume 20:Number 2(2023) Page Start: 133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Issue 10246 (25th July 2020) Authors: Mayer, Kenneth H; Molina, Jean-Michel; Thompson, Melanie A; Anderson, Peter L; Mounzer, Karam C; De Wet, Joss J; DeJesus, Edwin; Jessen, Heiko; Grant, Robert M; Ruane, Peter J; Wong, Pamela; Ebrahimi, Ramin; Zhong, Lijie; Mathias, Anita; Callebaut, Christian; Collins, Sean E; Das, Moupali; McCall... Journal: Lancet Issue: Volume 396:Issue 10246(2020) Page Start: 239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Estimation of new HIV diagnosis rates among high‐risk, PrEP‐eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United States. Issue 12 (20th December 2019) Authors: Mera, Robertino; Scheer, Susan; Carter, Christoph; Das, Moupali; Asubonteng, Julius; McCallister, Scott; Baeten, Jared Journal: Journal of the International AIDS Society Issue: Volume 22:Issue 12(2019) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Evidence of an Association of Increases in Pre-exposure Prophylaxis Coverage With Decreases in Human Immunodeficiency Virus Diagnosis Rates in the United States, 2012–2016. (25th February 2020) Authors: Smith, Dawn K; Sullivan, Patrick S; Cadwell, Betsy; Waller, Lance A; Siddiqi, Azfar; Mera-Giler, Robertino; Hu, Xiaohong; Hoover, Karen W; Harris, Norma S; McCallister, Scott Journal: Clinical infectious diseases Issue: Volume 71:Number 12(2020) Page Start: 3144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Infrequent Development of Drug Resistance in HIV-1-Infected Treatment-Naive Subjects after 96 Weeks of Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate. Issue 5 (July 2017) Authors: Margot, Nicolas; Cox, Stephanie; Das, Moupali; McCallister, Scott; Miller, Michael D; Callebaut, Christian Journal: Antiviral therapy Issue: Volume 22:Issue 5(2017) Page Start: 443 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. (1st July 2020) Authors: Yager, Jenna; Castillo-Mancilla, Jose; Ibrahim, Mustafa E.; Brooks, Kristina M.; McHugh, Cricket; Morrow, Mary; McCallister, Scott; Bushman, Lane R.; MaWhinney, Samantha; Kiser, Jennifer J.; Anderson, Peter L. Journal: Journal of acquired immune deficiency syndromes Issue: Volume 84:Number 3(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗